The import and export permits having been received in early December 2019, the extracts shipment arrived in Switzerland on 13 December. The latest development marks Switzerland as the 14th country to distribute Tilray’s medical cannabis products to patients in need. And, following this first shipment to the country, Tilray also anticipates exporting dried medical cannabis to Switzerland, offering patients an assortment of form factors to meet their varying medical needs.
“We’re proud to deliver Tilray’s medical cannabis to Swiss patients in need as we continue our expansion into Europe and around the globe,” said Sascha Mielcarek, Tilray’s Managing Director in Europe. “Tilray is committed to quality and patient safety and we look forward to significantly improving the quality of lives of Swiss patients through our medical cannabis products.”
Tilray has also recently announced that it has received an additional GMP certification for its EU campus in Cantanhede, Portugal. From here, the company plans to begin supplying its European partners with medical cannabis supplies from as early as 2020.